Partially plausible, unproven as stated. No supplied evidence directly examines Brazilian 2016 or 2022 mortality data among people aged 60+, so the hypothesis cannot be confirmed with the records available. What the evidence does establish is a consistent pattern of very low H3N2 vaccine effectiveness in the elderly, which is a necessary but not sufficient condition for the mismatch explanation.
Age-stratified VE data show a steep gradient: H3N2 VE of 58% in children versus 9% (US) and -11% (Denmark) in those over 65 during 2012/13, attributed to antigenic drift and narrower antibody breadth in the elderly . Notably, VE against B remained high (67-69%) in the elderly that season, meaning B-strain mismatch would need to be demonstrated specifically for the Brazilian 2016/2022 seasons rather than assumed.
Antigenic escape is real and quantifiable: H3N2 subclade K pseudoviruses were neutralised ~3-4.5-fold less than vaccine-matched strains both before and after vaccination, with the single HA mutation A186D driving both enhanced entry and reduced neutralisation . Recent H3N2 isolates also depend on the host factor Rab11B for binding and entry, mapped to the HA gene, indicating HA-driven changes in viral fitness beyond antigenicity . These HA-level changes could compound mismatch with immunosenescence: elderly vaccinees mount a humoral response skewed toward H3N2 with weaker H1N1 and B seroconversion β meaning even matched B components may induce weaker protection in this age group.
What would change the conclusion: season-specific Brazilian VE estimates, GISAID clade assignments of 2016/2022 Brazilian H3N2/B isolates versus that season's trivalent components, and subtype-stratified mortality among vaccinated versus unvaccinated elderly would allow direct causal testing. If mortality peaks persisted with well-matched vaccines and high measured VE, the mismatch explanation would be weakened.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.